Possible safety and efficacy outcome measures of Impamel III trials.

<p>Possible safety and efficacy outcome measures of Impamel III trials.</p

Mean and 95% CI for ES, CFR and hospitalization time.

<p>Trial data (solid line) and historic data (dashed line).</p

National treatment schedules for 2^nd stage <i>T.b. rhodesiense</i> HAT.

<p>NA:not applicable; i.v. melarsoprol injections at 24 hours intervals per series, each series spaced by 5 to 7 days resting periods; further variations of the schedules at local level.</p

Demographics and incidence of ES and death in historic patient files.

1<p>missing values for age: 18,</p>2<p>missing values for age: 3.</p

Overall study flow chart.

<p>Overall study flow chart.</p

Proof-of-concept trial: safety & efficacy outcomes at discharge and follow-up.

<p>NOTE:</p>a<p>two patients from Tanzania had an incomplete treatment and died outside the centre after family members took them back to the village to seek local treatment;</p>b<p>not related to HAT (Tanzania).</p

Serious adverse events, by SAE criterion.

<p>Serious adverse events, by SAE criterion.</p

Baseline characteristics of patient populations prior to data pooling.

<p>Note:</p>1<p>no suramin pre-treatment;</p>2<p>body mass index,</p>3<p>cerebrospinal fluid,</p>4<p>white blood cell.</p

Baseline demographic, diagnostic and clinical characteristics of the patients, by centre.

<p>Baseline demographic, diagnostic and clinical characteristics of the patients, by centre.</p

Flow diagram of the multicentre NECT trial for treatment of 2^nd stage HAT.

<p>The diagram includes detailed information on excluded patients.</p